Selected research
Industry Research
Pneumonia Treatment Drugs Industry Research Report 2026
Market perspective
The global Pneumonia Treatment Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pneumonia Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pneumonia Treatment Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pneumonia Treatment Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pneumonia Treatment Drugs include Teva Pharmaceutical, Sun Pharmaceutical, Novartis, Mylan, Pfizer, GlaxoSmithKline, AstraZeneca, Theravance Biopharma and Shinogi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pneumonia Treatment Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pneumonia Treatment Drugs Market by Company
Teva Pharmaceutical
Sun Pharmaceutical
Novartis
Mylan
Pfizer
GlaxoSmithKline
AstraZeneca
Theravance Biopharma
Shinogi
MSD
Medicines
Combioxin
Arsanis
Pneumonia Treatment Drugs Segment by Type
Vaccines
Vancomycin
Cephalosporin
Tetracyclines
Penicillin
Other Antibiotics
Immunotherapy Drug
Interferon
Fluoroquinolones
Macrolides
Pneumonia Treatment Drugs Segment by Application
Hospital
Clinic
Drugstore
Pneumonia Treatment Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Treatment Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pneumonia Treatment Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pneumonia Treatment Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pneumonia Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vaccines
- Vancomycin
- Cephalosporin
- Tetracyclines
- Penicillin
- Other Antibiotics
- Immunotherapy Drug
- Interferon
- Fluoroquinolones
- Macrolides
Applications
- Hospital
- Clinic
- Drugstore
Companies covered
- Teva Pharmaceutical
- Sun Pharmaceutical
- Novartis
- Mylan
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Theravance Biopharma
- Shinogi
- MSD
- Medicines
- Combioxin
- Arsanis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pneumonia Treatment Drugs Market Size (2021-2032)
- 2.2.2 Global Pneumonia Treatment Drugs Sales (2021-2032)
- 2.2.3 Global Pneumonia Treatment Drugs Market Average Price (2021-2032)
- 2.3 Pneumonia Treatment Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Vaccines
- 2.3.3 Vancomycin
- 2.3.4 Cephalosporin
- 2.3.5 Tetracyclines
- 2.3.6 Penicillin
- 2.3.7 Other Antibiotics
- 2.3.8 Immunotherapy Drug
- 2.3.9 Interferon
- 2.3.10 Fluoroquinolones
- 2.3.11 Macrolides
- 2.4 Pneumonia Treatment Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Drugstore
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pneumonia Treatment Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pneumonia Treatment Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Pneumonia Treatment Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Pneumonia Treatment Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Pneumonia Treatment Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pneumonia Treatment Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pneumonia Treatment Drugs, Product Type & Application
- 3.8 Global Manufacturers of Pneumonia Treatment Drugs, Established Date
- 3.9 Global Pneumonia Treatment Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical
- 4.1.1 Teva Pharmaceutical Company Information
- 4.1.2 Teva Pharmaceutical Business Overview
- 4.1.3 Teva Pharmaceutical Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Pneumonia Treatment Drugs Product Portfolio
- 4.1.5 Teva Pharmaceutical Recent Developments
- 4.2 Sun Pharmaceutical
- 4.2.1 Sun Pharmaceutical Company Information
- 4.2.2 Sun Pharmaceutical Business Overview
- 4.2.3 Sun Pharmaceutical Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sun Pharmaceutical Pneumonia Treatment Drugs Product Portfolio
- 4.2.5 Sun Pharmaceutical Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Pneumonia Treatment Drugs Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Pneumonia Treatment Drugs Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Pneumonia Treatment Drugs Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 GlaxoSmithKline
- 4.6.1 GlaxoSmithKline Company Information
- 4.6.2 GlaxoSmithKline Business Overview
- 4.6.3 GlaxoSmithKline Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GlaxoSmithKline Pneumonia Treatment Drugs Product Portfolio
- 4.6.5 GlaxoSmithKline Recent Developments
- 4.7 AstraZeneca
- 4.7.1 AstraZeneca Company Information
- 4.7.2 AstraZeneca Business Overview
- 4.7.3 AstraZeneca Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Pneumonia Treatment Drugs Product Portfolio
- 4.7.5 AstraZeneca Recent Developments
- 4.8 Theravance Biopharma
- 4.8.1 Theravance Biopharma Company Information
- 4.8.2 Theravance Biopharma Business Overview
- 4.8.3 Theravance Biopharma Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Theravance Biopharma Pneumonia Treatment Drugs Product Portfolio
- 4.8.5 Theravance Biopharma Recent Developments
- 4.9 Shinogi
- 4.9.1 Shinogi Company Information
- 4.9.2 Shinogi Business Overview
- 4.9.3 Shinogi Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Shinogi Pneumonia Treatment Drugs Product Portfolio
- 4.9.5 Shinogi Recent Developments
- 4.10 MSD
- 4.10.1 MSD Company Information
- 4.10.2 MSD Business Overview
- 4.10.3 MSD Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 MSD Pneumonia Treatment Drugs Product Portfolio
- 4.10.5 MSD Recent Developments
- 4.11 Medicines
- 4.11.1 Medicines Company Information
- 4.11.2 Medicines Business Overview
- 4.11.3 Medicines Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Medicines Pneumonia Treatment Drugs Product Portfolio
- 4.11.5 Medicines Recent Developments
- 4.12 Combioxin
- 4.12.1 Combioxin Company Information
- 4.12.2 Combioxin Business Overview
- 4.12.3 Combioxin Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Combioxin Pneumonia Treatment Drugs Product Portfolio
- 4.12.5 Combioxin Recent Developments
- 4.13 Arsanis
- 4.13.1 Arsanis Company Information
- 4.13.2 Arsanis Business Overview
- 4.13.3 Arsanis Pneumonia Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Arsanis Pneumonia Treatment Drugs Product Portfolio
- 4.13.5 Arsanis Recent Developments
5 Global Pneumonia Treatment Drugs Market Scenario by Region
- 5.1 Global Pneumonia Treatment Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pneumonia Treatment Drugs Sales by Region: 2021-2032
- 5.2.1 Global Pneumonia Treatment Drugs Sales by Region: 2021-2026
- 5.2.2 Global Pneumonia Treatment Drugs Sales by Region: 2027-2032
- 5.3 Global Pneumonia Treatment Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Pneumonia Treatment Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Pneumonia Treatment Drugs Revenue by Region: 2027-2032
- 5.4 North America Pneumonia Treatment Drugs Market Facts & Figures by Country
- 5.4.1 North America Pneumonia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pneumonia Treatment Drugs Sales by Country (2021-2032)
- 5.4.3 North America Pneumonia Treatment Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pneumonia Treatment Drugs Market Facts & Figures by Country
- 5.5.1 Europe Pneumonia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pneumonia Treatment Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Pneumonia Treatment Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pneumonia Treatment Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pneumonia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pneumonia Treatment Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pneumonia Treatment Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pneumonia Treatment Drugs Market Facts & Figures by Country
- 5.7.1 South America Pneumonia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pneumonia Treatment Drugs Sales by Country (2021-2032)
- 5.7.3 South America Pneumonia Treatment Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pneumonia Treatment Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pneumonia Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pneumonia Treatment Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pneumonia Treatment Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pneumonia Treatment Drugs Sales by Type (2021-2032)
- 6.1.1 Global Pneumonia Treatment Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Pneumonia Treatment Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Pneumonia Treatment Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Pneumonia Treatment Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pneumonia Treatment Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Pneumonia Treatment Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pneumonia Treatment Drugs Sales by Application (2021-2032)
- 7.1.1 Global Pneumonia Treatment Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Pneumonia Treatment Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Pneumonia Treatment Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Pneumonia Treatment Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pneumonia Treatment Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Pneumonia Treatment Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pneumonia Treatment Drugs Value Chain Analysis
- 8.1.1 Pneumonia Treatment Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pneumonia Treatment Drugs Production Mode & Process
- 8.2 Pneumonia Treatment Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pneumonia Treatment Drugs Distributors
- 8.2.3 Pneumonia Treatment Drugs Customers
9 Global Pneumonia Treatment Drugs Analyzing Market Dynamics
- 9.1 Pneumonia Treatment Drugs Industry Trends
- 9.2 Pneumonia Treatment Drugs Industry Drivers
- 9.3 Pneumonia Treatment Drugs Industry Opportunities and Challenges
- 9.4 Pneumonia Treatment Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst